Drug Profile
Encochleated amikacin - Matinas BioPharma
Alternative Names: Amikacin-LNC; AmK-LNC; C-Amikacin; MAT 2501Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Aquarius Biotechnologies
- Developer Matinas BioPharma
- Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gram-negative infections; Nontuberculous mycobacterium infections
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Nontuberculous-mycobacterium-infections(In volunteers) in USA (PO)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (PO)
- 13 May 2022 Pharmacokinetics and adverse events data from a preclinical trial released by Matinas BioPharma